Subjects that remain eligible after the run-in period will be randomized 15:6 (for at total of 21 randomized subjects) to receive either 440 mg of RMJH-111b or placebo orally bid for a 7-day treatment period. Follow-up assessments will be performed 24 hours and 7 days after the last dose of study drug.